<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01729481</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005471-17</org_study_id>
    <nct_id>NCT01729481</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer</brief_title>
  <acronym>ML22774</acronym>
  <official_title>Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the current study it is examined whether patients with good risk factors (age &lt;75 years,&#xD;
      total serum bilirubin &lt; 1,5xULN, no history of cardiovascular diseases) treated with&#xD;
      gemcitabine and erlotinib who developed skin rash of any grade during the first 4 weeks of&#xD;
      treatment have a comparable outcome as patients who receive FOLFIRINOX.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study by Burris et al. 1997 revealed a superiority of gemcitabine vs. 5-FU in terms of&#xD;
      improvement of general condition, pain symptoms and overall survival in patients with locally&#xD;
      advanced or metastatic pancreatic cancer. Subsequently, gemcitabine was established as a&#xD;
      standard treatment for locally advanced and metastatic pancreatic cancer.&#xD;
&#xD;
      In a series of studies gemcitabine was combined with other chemotherapeutic agents or&#xD;
      targeted therapies. For the first time, the PA.03 study showed a significant improvement of&#xD;
      overall survival. Patients who were treated with gemcitabine plus erlotinib had a survival of&#xD;
      6.24 months, compared with 5.91 months for those treated with gemcitabine plus placebo (HR&#xD;
      0.82, 95% CI 0.69-0.99, p=0.038). The one-year-survival rate was 23% for gemcitabine plus&#xD;
      erlotinib vs. 17% for gemcitabine plus placebo.&#xD;
&#xD;
      In a subgroup analysis of the PA.03 study, patients developing a skin rash NCI CTC ≥ grade 2&#xD;
      had an advanced survival (one-year-survival rate 43%) vs. those with grade 1 or 0&#xD;
      (one-year-survival rate 16% and 9%, respectively). Later studies confirmed the correlation&#xD;
      between skin rash and survival.&#xD;
&#xD;
      While patients developing a skin rash of any grade seem to profit most from treatment with&#xD;
      erlotinib, the prognosis for those without rash is rather dismal. In this population,&#xD;
      survival varied between 3.3 and 4.8 months in clinical trials (Verslype et al. 2009, Boeck et&#xD;
      al. 2010, Manzano et al. 2010). In this patients, a modification of the treatment strategy&#xD;
      should be considered. Which kind of treatment might lead to optimal results in these patients&#xD;
      is not yet clear.&#xD;
&#xD;
      In patients with excellent general condition complying with further prerequisits (age &lt;75&#xD;
      years, total serum bilirubin &lt; 1,5xULN, no history of cardiovascular diseases) the French&#xD;
      Prodige study-group could show a statistical superiority for the gemcitabine-free&#xD;
      FOLFIRINOX-scheme in terms of overall survival, progression free survival and response rate&#xD;
      compared to gemcitabine alone. However, this superiority was gained at the expense of&#xD;
      treatment tolerability. During treatment with FOLFIRINOX a grade 3-4 neutropenia was observed&#xD;
      in 5.4% and a grade 3-4 diarrhea in 12.7% of patients (Conroy et al. 2011). For patients who&#xD;
      comply with the above-named criteria FOLFIRINOX is considered an established standard of&#xD;
      care.&#xD;
&#xD;
      If a comparable efficacy of gemcitabine plus erlotinib with the published FOLFIRINOX data can&#xD;
      be seen in the selected population, this would favour, due to the worse tolerability of&#xD;
      FOLFIRINOX, the use of gemcitabine plus erlotinib.&#xD;
&#xD;
      In summary, the following selections are conducted during the study:&#xD;
&#xD;
        1. Selection due to the inclusion criteria for treatment with FOLFIRINOX provided by Conroy&#xD;
           et al.&#xD;
&#xD;
        2. Selection due to the development of a skin rash within four weeks of treatment&#xD;
&#xD;
        3. No signs of clinical tumour progression within the run-in phase within the first four&#xD;
           weeks of treatment&#xD;
&#xD;
      Patients who do not develope a skin rash of any grade should be treated with FOLFIRINOX. The&#xD;
      efficacy of FOLFIRINOX in rash-negative patients has not yet been investigated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year Survial rate of &quot;good-risk&quot; patients</measure>
    <time_frame>Follow-Up Phase (1.5 years)</time_frame>
    <description>1-year Survial rate of &quot;good-risk&quot; patients of patients under gemcitabine plus erlotinib with RASH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evalutation of overall response rate, disease control rate and progression free survival</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Evaluation of Parameters by RASH positve and negative patients:&#xD;
ORR&#xD;
DCR&#xD;
PFS&#xD;
OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events</measure>
    <time_frame>Treatment Phase (1.5 Years)</time_frame>
    <description>Assesment with NCI-CTCAE V4.0 Evalutation of side effects including picture documentation of skin-rash</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Translational Projects</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Evaluation of Parameters for EGFR signal transduction&#xD;
Evaluation Molecularbiological Parametrs of RASH&#xD;
Picture Documentation of RASH. Corellation with clinical and molecularbiological Parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Metastatic Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>RASH positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Run-In-Phase during 4 weeks:&#xD;
Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly&#xD;
Thereafter Treatment in patients with RASH-positve outcome after 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RASH-negative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Run-In-Phase during 4 weeks:&#xD;
Gemcitabine 1000 mg/m², weekly Erlotinib 100 mg, weekly&#xD;
RASH-negative patients quit treatment with Gemcitabine + Erlotinib and continue treatment with FOLFIRINOX:&#xD;
Oxaliplatin 85mg/m2 Irinotecan 180 mg/m2 Folinic acid 400 mg/m2 5-FU 400 mg/m2 bolus iv 5-FU 2400 mg/m2 46-hours continous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m² iv weekly</description>
    <arm_group_label>RASH positive</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>100mg, once per day</description>
    <arm_group_label>RASH positive</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m², q2weeks</description>
    <arm_group_label>RASH-negative</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic Acid</intervention_name>
    <description>400 mg/m², q2weeks</description>
    <arm_group_label>RASH-negative</arm_group_label>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m², q2weeks</description>
    <arm_group_label>RASH-negative</arm_group_label>
    <other_name>Campto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks</description>
    <arm_group_label>RASH-negative</arm_group_label>
    <other_name>5-Flourouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically (not cytologically) confirmed metastatic pancreatic adenocarcinoma&#xD;
             (stage IV according to UICC, each T, each N, M1 according to TNM)&#xD;
&#xD;
          -  At least one measurable index lesion (CT or MRI) according to RECIST criteria (V 1.1)&#xD;
&#xD;
          -  ECOG PS 0 and 1&#xD;
&#xD;
          -  Age 18-75 years&#xD;
&#xD;
          -  Serum bilirubin ≤1,5x ULN (a placed biliary tract stent without concurrent cholangitis&#xD;
             is not considered a contraindication)&#xD;
&#xD;
          -  Availability of tumour samples (no cytologic samples)&#xD;
&#xD;
          -  Written informed consent by the patient for collecting blood- and tumour-samples for&#xD;
             translational research according to study protocol&#xD;
&#xD;
          -  Live expectancy of at least three months&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Negative pregnancy test in women with childbearing potential (to be performed within 7&#xD;
             days prior to treatment start)&#xD;
&#xD;
          -  Adequate kidney-, liver- and bone-marrow function: neutrophils &gt;= 1500/µl, platelets&#xD;
             &gt;= 100.000/µ, and hemoglobin &gt;= 8g/dl, liver transaminases&lt;= 2,5x ULN, in case of&#xD;
             liver metastases &lt;= 5x ULN, serum creatinine &lt;= 1,25x ULN, creatinine clearance ≥ 30&#xD;
             ml/min&#xD;
&#xD;
          -  Legal capacity of the patient&#xD;
&#xD;
          -  Option for constant long-term follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Resectable pancreatic carcinoma&#xD;
&#xD;
          -  Locally advanced pancreatic cancer (non-resectable tumour without distant metastasis)&#xD;
&#xD;
          -  Previous palliative chemotherapy for metastatic or locally advanced, non-resectable&#xD;
             pancreatic cancer&#xD;
&#xD;
          -  Previous palliative radiation or chemoradiation for locally advanced, non-resectable&#xD;
             pancreatic cancer&#xD;
&#xD;
          -  Radiation therapy within four weeks prior to study enrolment or radiation of indicator&#xD;
             lesions&#xD;
&#xD;
          -  Adjuvant Chemotherapy or Radiochemotherapy for pancreatic cancer ≤ 6 months prior to&#xD;
             study ernrolment&#xD;
&#xD;
          -  All previously occurred metastatic cancers or cured neoplasias diagnosed within the&#xD;
             last 5 years before study enrolment&#xD;
&#xD;
          -  Major surgery within 2 weeks before study start&#xD;
&#xD;
          -  Chronic diarrhea&#xD;
&#xD;
          -  Known glucuronidation-deficiency (Gilbert´s syndrome)&#xD;
&#xD;
          -  Acute or subacute ileus or chronic inflammatory bowel disease&#xD;
&#xD;
          -  Preexisting polyneuropathy &gt; Grade I according to NCI-CTCAE v.4.0&#xD;
&#xD;
          -  Relevant comorbidities which might impair patient eligibility or safety for study&#xD;
             participation like active infections, hepatic, renal or metabolic diseases&#xD;
&#xD;
          -  Clinically significant cardiovascular diseases within 12 months prior to study start&#xD;
             (e.g. unstable angina pectoris, myocardial infarction, heart failure ≥ NYHA II,&#xD;
             cardiac arrhythmias requiring treatment)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Heinemann, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Department III and Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-muenchen.de/Pankreaszentrum-Muenchen/de/startseitenmeldungen/index.html</url>
    <description>Homepage of the PancreasCenter at LMU Munich</description>
  </link>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>October 23, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2012</study_first_posted>
  <last_update_submitted>July 16, 2017</last_update_submitted>
  <last_update_submitted_qc>July 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Volker Heinemann</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

